Pay in 4 interest-free payments of $5.33 Learn more
Ships within 48 hours · Estimated delivery Oct 23 - Oct 28
India GLP-1 Receptor Agonists Obesity Drugs Market Insight The India GLP-1 receptor agonists obesity drugs accounted for the largest revenue share in Asia Pacific in 2024, driven by a growing obesity burden, increasing healthcare awareness, and the rapid expansion of urban healthcare infrastructure
Benefits of Exercise and GLP-1 Therapy According to the research, exercise and GLP-1 therapy can: Generate $182 million in health and economic value over 10 years Deliver a 59 per cent return on investment within 10 years Generate $1.4 billion in value over 30 years Deliver a 457 per cent return on investment over 30 years Improve long-term health outcomes Reduce future healthcare costs Preserve muscle mass, strength, mobility and bone health Improve long-term weight maintenance Reduce weight regain after treatment ends Prevent hundreds of serious health events, including heart attacks, strokes and heart failure Reduce the need for knee and hip replacements A Call to Integrate Exercise and GLP-1 Therapy In response to the findings, AUSactive has joined leading industry organisations from Australia, New Zealand, Canada, the United Kingdom and the United States
The compound has a half-life of approximately six days, which allows for convenient once-weekly dosing
FDA has approved an expanded indication for Wegovy (semaglutide 2.4 mg) in adults with noncirrhotic MASH (F2F3), alongside diet and exercise
7c, e, f)
